|
|
Article: Statins Will Remain the Dominant Class in Treatment of Coronary Heart Disease, Although Their Market Share Will Decline More Than 20%.
- Article from:
- PR Newswire
- Article date:
- February 15, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Pfizer Will Aggressively Market Combination Pill for Treating the Disease, According to a New Report from Decision Resources
WALTHAM, Mass., Feb. 15 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that statins will remain the dominant class in coronary heart disease treatment although their market share will drop from 55% in 2004 to 33% in 2014.
The new Pharmacor report entitled Coronary Heart Disease finds that generic competition will aggressively erode the market share of statins but the introduction of novel therapies in combination with statins ...